Ferric derisomaltose is commonly used to help with the management of iron deficiency anemia (IDA) in adult patients. This medication plays a role in managing the symptoms related to systemic imbalance that interfere with daily functioning.

The treatment is considered relevant in specific clinical scenarios involving IDA, such as when patients have an intolerance to oral iron supplements or have experienced an unsatisfactory response. It is commonly used to help with patients with IDA associated with non-hemodialysis dependent chronic kidney disease (NDD-CKD).

This medication is utilized in these clinical contexts. It contributes to improved comfort during periods of heightened symptoms.

The intravenous replacement helps patients cope more steadily with symptom fluctuations. This provides support that helps ease the overall symptom burden associated with chronic iron deficiency.

Quick Fact: Provides supportive relief for symptoms related to physical discomfort.

Regulatory References

1. U.S. Department of Veterans Affairs clinical monograph

Eligibility Map: Who Can and Cannot Use Vanafer

Vanafer (iron sucrose) is indicated for the treatment of iron deficiency anemia (IDA) in patients with Chronic Kidney Disease (CKD). The official regulatory labeling sets clear rules for eligibility and absolute contraindications.

---

Populations for Whom Use is Contraindicated

Classification	Population
Absolute Contraindication	Patients with known hypersensitivity to iron sucrose or its excipients.
Absolute Contraindication	Patients with evidence of iron overload (e.g., high ferritin levels).
Absolute Contraindication	Patients with anemia not caused by iron deficiency (e.g., hereditary iron disorders).

---

Age and Physiological Eligibility Status

Population	Status in Regulatory Documents
Adult Patients	Approved for use in CKD patients with IDA.
Pediatric Patients	Approved for use in patients 2 years of age and older.
Infants (< 2 years)	Safety and efficacy not established by regulatory agencies.
Pregnancy	Use is restricted and generally avoided in the first trimester; caution is advised during the second and third trimesters.
Older Adults	Use requires caution due to a greater frequency of decreased organ function.

---

Condition-Specific Eligibility Restrictions

Patients with liver dysfunction or a history of severe atopic allergy (such as asthma or eczema) require conditional use only after careful risk assessment, as stated in official product labeling. Administration must also be stopped in patients with active bacterial infection (bacteraemia).

Connection to the Overall Eligibility Profile

Regulatory documents define Vanafer's eligible population by requiring a specific diagnosis (IDA in CKD) and strictly excluding any patient with evidence of iron excess or a history of allergic reaction to the product. Use outside the approved age group of 2 years and older is officially classified as not established.

Interaction Map: Interactions with other medicines and products — official regulatory information for Vanafer (Iron Sucrose)

Category	Official Regulatory Information
Medicinal product categories with documented interactions	Oral Iron Preparations (e.g., Ferrous Sulfate, Ferrous Gluconate).
Specific interacting medicines (if explicitly listed)	Oral iron preparations (as a class).
Mechanistic basis of interactions (only if stated in label)	Reduction in absorption (pharmacokinetic interference on the oral agent). Note: Metabolic (e.g., CYP) interaction studies are not documented.
Timing-based interaction rules (if applicable)	Oral iron therapy should be started at least 5 days after the last injection of Vanafer.
Interaction-related restrictions	Use is restricted in patients with evidence of iron overload or hereditary disturbances of iron utilization.

Interaction classifications (high-level)

Classification	Official Regulatory Information
Interaction severity classification	Not explicitly classified by severity level; cited as requiring a mandatory timing constraint with oral iron.
Interaction-context constraints	Contraindicated in cases of known hypersensitivity to the drug or excipients.

Official interaction statements and overall profile: The primary interaction pattern documented in regulatory labeling is a pharmacokinetic interference that results in the reduction of the oral agent’s exposure when Vanafer is concurrently administered. This exposure-modifying interaction with all forms of oral iron requires the mandatory separation of dosing by at least five days after the final Vanafer injection. Official documents confirm that comprehensive drug-drug interaction studies involving metabolic pathways, such as the cytochrome P450 enzyme systems or transporter proteins, have not been documented for Vanafer. The overall regulatory profile is also defined by formal restrictions that prohibit its use in patients with confirmed iron overload, in cases where the anemia is not caused by iron deficiency, or where known hypersensitivity to the drug or its excipients exists. These constraints structure the product's official interaction status.

Targeted Delivery via the Reticuloendothelial System (RES)

Vanafer is a stable complex with physicochemical properties that facilitate its uptake by macrophages within the Reticuloendothelial System (RES). This mechanism utilizes targeted uptake, allowing for the controlled dissociation of the iron core within the macrophage, which subsequently mobilizes the iron into the bloodstream. This physiological process establishes the rate of iron mobilization, modulating its availability for plasma transport and cellular storage.

---

Substrate Supply to the Erythropoiesis Pathway

The iron released by the macrophages is immediately captured by the plasma protein transferrin and rapidly transported to the bone marrow. Here, the iron is delivered to erythroid precursor cells for integration into the heme synthesis pathway. By providing this crucial substrate directly to the site of red blood cell production, the drug provides the substrate necessary for the synthesis of hemoglobin. The resulting physiological effect is the increase in iron content within cellular storage proteins (ferritin) and an increase in the blood’s capacity to transport oxygen.

Vanafer is an iron replacement product administered only intravenously (IV) under the supervision of a healthcare professional, typically in a hospital or dialysis center setting. Its usage follows specific protocols based on the patient's type of chronic kidney disease (CKD).

The standard adult treatment involves administering a total cumulative dose of 1000 mg of elemental iron. For patients undergoing hemodialysis, the general pattern is a dose of 100 mg of elemental iron given during each consecutive dialysis session, usually within the first hour. For non-dialysis-dependent adult CKD patients, the 1000 mg course is structured as five separate doses of 200 mg given over a 14-day period.

Proper preparation is essential for administration. If given as an infusion, Vanafer must be diluted exclusively with 0.9% Sodium Chloride Injection to achieve a concentration of 1–2 mg/mL. The minimum infusion time for a 100 mg dose is 15 minutes, while doses up to 200 mg may be given as a slow IV injection over 2 to 5 minutes. The injection must not be physically mixed with other intravenous medications.

Specific maintenance dosing is defined for pediatric patients (age 2 years and older). The recommended maintenance dose is 0.5 mg/kg of elemental iron, not exceeding 100 mg per dose. This regimen is typically administered every two or four weeks for a duration of 12 weeks, depending on whether the child is on hemodialysis. The entire treatment course may be repeated if iron deficiency recurs after completion of the initial 1000 mg total dose.

Research Evidence / Overview of Studies for Vanafer

Vanafer (iron sucrose) was studied for its use as an intravenous iron replacement. The available research comes primarily from clinical trials, including randomized controlled trials (RCTs), as well as large observational studies and meta-analyses, all researching its role in iron deficiency anemia.

---

Evidence for Use in Iron Deficiency Anemia in Hemodialysis Patients

The most substantial research base focused on adult patients with end-stage kidney disease who are receiving maintenance hemodialysis. Research explored the relationship between Vanafer and key iron measurements in the blood, known as biomarkers, such as serum ferritin and transferrin saturation (TSAT). Studies reported measurements of iron storage biomarkers generally increased from baseline after Vanafer was administered, and research reported observed shifts in hemoglobin concentrations from baseline across the short-term trials. Research describes the patterns of association between iron replacement and the patient's need for erythropoiesis-stimulating agents (ESAs).

Long-term effects are not fully established by definitive randomized controlled trials. While long-term observational studies research examined outcomes related to systemic or functional imbalance including hospitalization, certainty remains low because the observational setting data show patterns related to existing differences between patient groups.

---

Evidence for Use in Non-Dialysis Dependent Chronic Kidney Disease

Research examined the use of Vanafer in adult patients with Chronic Kidney Disease (CKD Stages 3 to 5) who have iron deficiency anemia but are not yet on dialysis. The research primarily consisted of randomized controlled trials (RCTs) that evaluated Vanafer against oral iron supplements. Studies reported that the measured rate of achieving a target increase in hemoglobin concentration showed an observed pattern of a higher measured rate for the intravenous therapy when evaluated against oral iron supplementation in some trials.

Evidence quality varies across studies in the NDD-CKD group. Data are still emerging regarding the long-term impact on kidney function itself, and comparative evidence is lacking against all the newer intravenous iron formulations for this specific predialysis population.

---

What is Still Uncertain About Vanafer Research

A key area of uncertainty is the long-term impact on outcomes linked to inflammatory or irritative states and infection risk, particularly when Vanafer was studied for its impact over extended periods. The comparative evidence is lacking in some areas, meaning the long-term differences in physiological outcomes tracked in the studies and the required re-treatment patterns between Vanafer and every available alternative are not fully characterized across all relevant populations.

Key Studies & References NICE Guideline NG203: Chronic kidney disease: assessment and management (Used to inform comparison context with oral iron)

Common questions about Vanafer (FAQ)

---

Q: What is the minimum recommended infusion time for Vanafer?

Official product information describes the minimum infusion time for a 100 mg dose as 15 minutes. Additionally, doses up to 200 mg may be administered as a slow intravenous injection over a period of 2 to 5 minutes. Administration is always performed by a healthcare professional in a clinical setting.

---

Q: How does Vanafer's iron get into the bloodstream?

Regulatory data explains that the iron component is processed by a network of cells in the body before being captured by a protein called transferrin. Transferrin then transports the iron to the bone marrow, where it is used by erythroid precursor cells to create hemoglobin for red blood cells.

---

Q: Why do I need to stop taking my oral iron supplements after starting Vanafer?

Official drug interaction labeling indicates that Vanafer may interfere with and reduce the absorption of oral iron preparations. Therefore, a mandatory separation of dosing is required: oral iron therapy should be initiated at least five days after the final Vanafer injection.

---

Q: Is Vanafer considered a first-line treatment for iron deficiency anemia?

The official indication for Vanafer is the treatment of iron deficiency anemia in adult and pediatric patients (age 2 years and older) with chronic kidney disease (CKD). The product is indicated for specific populations, and official documents note its use when oral iron supplements may be insufficient or poorly tolerated.

---

Q: How long does the effect of Vanafer last?

The treatment course is designed to replenish the body’s iron stores. Product information states that the treatment course may be repeated if iron deficiency recurs after the initial course has been completed. The need for a repeat course is determined by a healthcare provider.

---

Q: What is the shelf life of Vanafer after the vial is first opened?

Official guidelines state the product should be used immediately after the vial is first opened. If Vanafer is diluted in 0.9% Sodium Chloride solution, regulatory documents confirm it is chemically and physically stable for seven hours, provided it is kept at the proper temperature.

Storage and Disposal of Venofer (Iron Sucrose Injection)

Official regulatory guidelines define strict conditions for the storage and disposal of Venofer (iron sucrose injection, USP).

---

Storage Requirements

• Temperature: Store at 20 C to 25 C (68 F to 77 F), defined as Controlled Room Temperature. Excursions are permitted between 15 C and 30 C.
• Protection: The product must be stored in the original container to protect it and must not be frozen.
• Child Safety: Keep out of the reach of children.
• Stability: If diluted in 0.9% Sodium Chloride solution, the product is chemically and physically stable for seven hours at 25 C. The solution must be inspected visually for particulates before use.

---

Disposal Instructions

Unused or expired Venofer and associated waste must be disposed of as pharmaceutical waste in accordance with local, state, and federal regulations. Sharps, such as needles and syringes, must be discarded immediately into an FDA-cleared sharps disposal container.